Betta Pharmaceuticals (300558.SZ): BPI-572270 capsules approved for clinical trials in Australia

Zhitong Finance App News, Betta Pharmaceutical (300558.SZ) issued an announcement. The BPI-572270 capsules declared by the company's wholly-owned subsidiary Hangzhou Jingyao Biotechnology Co., Ltd. (hereinafter referred to as “Jingyao Biotech”) for phase I/II clinical studies on advanced solid tumor patients with specific RAS mutations have been reviewed and approved by the Australian Human Research Ethics Committee (“HREC”) and completed the Australian Drug Administration (“TGA” for short) ) Clinical trial registration. This is the company's first new drug approved for clinical trials in Australia.